VYNE Therapeutics (NASDAQ:VYNE) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

VYNE Therapeutics (NASDAQ:VYNE) posted its quarterly earnings results on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.10, FiscalAI reports. The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative net margin of 4,646.14% and a negative return on equity of 74.86%.

VYNE Therapeutics Price Performance

Shares of NASDAQ:VYNE opened at $0.67 on Friday. The company has a market cap of $22.32 million, a price-to-earnings ratio of -0.86 and a beta of 2.00. The firm has a 50 day simple moving average of $0.62 and a 200 day simple moving average of $0.54. VYNE Therapeutics has a one year low of $0.28 and a one year high of $1.96.

Hedge Funds Weigh In On VYNE Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Investments LP bought a new position in VYNE Therapeutics in the 3rd quarter valued at approximately $74,000. ADAR1 Capital Management LLC bought a new position in shares of VYNE Therapeutics during the fourth quarter valued at $147,000. Jane Street Group LLC acquired a new position in shares of VYNE Therapeutics during the second quarter worth $206,000. Nantahala Capital Management LLC acquired a new position in shares of VYNE Therapeutics during the fourth quarter worth $580,000. Finally, Anson Funds Management LP acquired a new position in shares of VYNE Therapeutics during the fourth quarter worth $739,000. Institutional investors own 83.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on VYNE shares. Wall Street Zen raised shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.